Abbott Laboratories (ABT) Stock Analysis & Winston Score
Abbott Laboratories makes medical products that help doctors diagnose and treat patients. Its main businesses include medical devices like heart stents and continuous glucose monitors (sold under the FreeStyle Libre brand), diagnostic tests used in hospitals and labs, and nutritional products like Similac baby formula and Ensure. Abbott sells to hospitals, clinics, pharmacies, and everyday consumers around the world. Abbott earns money by selling physical products — devices, test kits, and nutrition products — across more than 160 countries. It is a large, diversified healthcare company with roughly $20 billion in annual revenue, and its scale and well-known brands give it a durable competitive position. The FreeStyle Libre glucose monitor is a fast-growing product in the expanding diabetes management market, but Abbott faces real competition from rivals like Dexcom in that space, and any product safety issues — as seen with its 2022 baby formula recall — can cause significant financial and reputational damage.
Winston Score: 48/100 — Average
Mixed quality — meaningful strengths and weaknesses.
- Quality: Good (15/30)
- Growth: Weak (4/20)
- Cash Flow: Exceptional (9/10)
- Stability: Strong (8/10)
- Valuation: Strong (7/10)
- Ownership: Weak (2/15)
Key Facts
Price: $100.67
Market Cap: $175.3B
Sector: Healthcare
Industry: Medical - Devices



